The new fund offers or NFOs of the schemes are open for subscription and will close on January 30. The schemes will re-open for continuous sale and repurchase within five business days from the date of allotment.
WhiteOak Capital Banking & Financial Services Fund
WhiteOak Capital Banking & Financial Services Fund is an open-ended equity scheme investing in the banking and financial services sector.
The investment objective of the scheme is to provide long-term capital appreciation by investing predominantly in equity and equity-related instruments of banks and companies engaged in the financial services sector.
The scheme will be benchmarked against Nifty Financial Services Total Return Index (TRI). The scheme will be managed by Trupti Agrawal, Piyush Baranwal, Ramesh Mantri, and Shariq Merchant.
The minimum application amount will be Rs 500 and in multiples of Re 1 thereafter. The minimum application amount for weekly, fortnightly, and monthly SIP will be Rs 100 (plus in multiple of Re 1) with minimum six instalments. The scheme will invest 80-100% in equity and equity-related instruments of banks and companies engaged in financial services sector, 0-20% in equity and equity related instruments companies other than engaged in financial services sector, 0-20% in debt securities and money market instruments, and 0-10% in units issued by REITS and InVITs. The scheme will follow a bottom-up approach to stock-picking and choose companies which are expected to get benefitted from the growth of the banking and financial services sector.
The scheme is suitable for investors who are seeking long-term capital appreciation and want investment predominantly in equity and equity related instruments in banking and financial services sector.
WhiteOak Capital Pharma and Healthcare Fund
WhiteOak Capital Pharma and Healthcare Fund is an open-ended equity scheme investing in the pharma and healthcare sector.
The investment objective of the scheme is to provide long-term capital appreciation by investing predominantly in equity and equity-related instruments of pharma and healthcare companies.
The scheme will be benchmarked against S&P BSE Healthcare TRI. The scheme will be managed by Ramesh Mantri, Dheeresh Pathak, Piyush Baranwal (debt investments), and Shariq Merchant (overseas investments).
The minimum application amount will be Rs 500 and in multiples of Re 1 thereafter. The minimum application amount for weekly, fortnightly, and monthly SIP will be Rs 100 (plus in multiple of Re 1) with minimum six instalments.
The scheme will invest 80-100% in equity and equity-related instruments of pharma and healthcare companies, 0-20% in equity and equity related instruments companies other than pharma and healthcare companies, 0-20% in debt securities and money market instruments, and 0-10% in units issued by REITS and InVITs.
The scheme will be actively managed and will follow a bottom-up approach to stock-picking and choose companies which are expected to get benefitted from the growth in the pharma and healthcare space.
The scheme is suitable for investors who are seeking long-term capital appreciation and want investment predominantly in equity and equity related instruments of pharma and healthcare companies.
Should you invest?
ETMutualFunds believes that investors should invest in an NFO only if it is offering something unique or something extra to already available options. Otherwise, they are better off with an existing scheme with a long, consistent performance record.
There are around 18 schemes in the banking and financial services category. Around 11 schemes have a performance record of five years. Sundaram Financial Services Opportunities Fund, the topper in the category, offered 18.20% in a five year horizon. Tata Banking & Financial Services Fund and Invesco India Financial Services Fund gave around 15%. Three schemes gave around 14%.
There are around 13 schemes in the pharma and healthcare sectoral category. Four schemes have a performance record of around seven years. Nippon India Pharma Fund, the topper in the category, gave 17.28% in a seven year period. Tata India Pharma & Healthcare Fund gave 15.04%. UTI Healthcare Fund and SBI Healthcare Opportunities Fund gave 13.47% and 13.29% respectively.
